What is this summary about?This summary describes the main findings of the MANEUVER clinical trial for pimicotinib, a once-daily treatment. The goal was to see if pimicotinib could significantly reduce tumor size after 24 weeks of treatment in clinical trial participants with tenosynovial giant cell tumor (TGCT) comp...
H. Gelderblom, Xiao-Hui Niu, S. Stacchiotti et al.· Future Oncology· 0 citations
Current DPYD genotyping panels used to prevent fluoropyrimidine (FL)-related toxicity explain only a limited proportion of severe adverse events. The clinical relevance, beyond current testing, of additional DPYD variants, including DPYD⁎6 (c.2194G>A, rs1801160), DPYD c.496A>G (rs2297595), and DPYD⁎9A (c.85T>C, rs18012...
E. De Mattia, J. Polesel, M. van der Lee et al.· Pharmacological Research· 0 citations
Combination therapies are widely used in oncology due to their potential to improve therapeutic efficacy and overcome drug resistance. However, these potential advantages must be weighed against added toxicity, treatment burden, and costs. In this commentary, we examine some recent examples of divergent opinions by the...
F. de Jong, L. Douma, P. Baas et al.· Journal of the National Canc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.